Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: A randomized evaluation of early vs late administration of recombinant human G-CSF

Bone Marrow Transplantation

Volumn 44, Issue 12, 2009, Pages 779-783

  Ozcelik, T ^a   Topcuoglu, P ^b   Beksac, M ^b   Ozcan, M ^b   Arat, M ^b   Bykl, Z ^b   Bakanay, S M ^b   Ilhan, O ^b   Gurman, G ^b   Arslan, O ^b   Demirer, T ^b  

^a ULUDAG UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

G CSF; Mobilization; SCT

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; APHERESIS; ARTICLE; CANCER RADIOTHERAPY; CELL COUNT; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; MALE; MULTIPLE MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL MOBILIZATION; TREATMENT RESPONSE;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKAPHERESIS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 75049084126     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.161     Document Type: Article

References (25)

1. Demirer T, Bensinger WI, Buckner CD. Peripheral blood stem cell mobilization for high-dose chemotherapy. J Hematother 1999; 8: 103-113.
2. Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwartz G et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colonystimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-3044.
3. Haas R, Hohaus S, Egerer G, Ehrhardt R, Witt B, Hunstein W. Recombinant human granulocyte-macrophage colonystimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. Bone Marrow Transplant 1992; 9: 459-465.
4. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
5. Demirer T, Buckner CD, Bensinger WI. Optimization of peripheral blood stem cell mobilization. Stem Cells 1996; 14: 106-116.
6. Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937-941.
7. Demirer T, Buckner CD, Storer B, Appelbaum FR, Storb R, Bensinger WI. The effect of different chemotherapy regimens on peripheral blood stem cell mobilization yield. J Clin Oncol 1997; 15: 684-690.
8. Kotasek D, Shepherd KM, Sage RE, Dale BM, Norman JE, Charles P et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11-17.
9. Mendrone Jr A, Arrais CA, Saboya R, Chamone Dde A, Dulley FL. Factors affecting hematopoietic progenitor cell mobilization: An analysis of 307 patients. Transfus Apher Sci 2008; 39: 187-192.
10. Weaver CH, Birch R, Greco FA, Schwartzberg L, McAneny B, Moore M et al. Mobilization and harvesting of peripheral blood stem cells: Randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100: 338-347.
11. Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colonystimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116: 468-474.
12. André M, Baudoux E, Bron D, Canon JL, D'Hondt V, Fassotte MF et al. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003; 43: 50-57.
13. Demirer T, Arat M, Koç H, Ustun C, Ozcan M, Gurman G et al. Stem cell mobilization with cyclophosphamide, paclitaxel (or etoposide) and recombinant granulocyte colony stimulating factor (rhG-CSF): I?bni Sina experience. Turkish Journal of Hematology 1999; 16: 83-84.
14. Demirer T, Ayli M, Dagli M, Haznedar R, Genc Y, Fen T et al. Influence of post-transplant recombinant human granulocyte-colony stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol 2002; 118: 1104-1111.
15. Jacoub JF, Suryadevara U, Pereyra V, Coló n D, Fontelonga A, Mackintosh FR et al. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Exp Hematol 2006; 34: 1443-1450.
16. Mollee P, Pereira D, Nagy T, Song K, Saragosa R, Keating A et al. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant 2002; 30: 273-278.
17. Lefrère F, Zohar S, Ghez D, Delarue R, Audat F, Suarez F et al. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 mg/kg for progenitor cell mobilization: Results from a monocentric study of 82 patients. Bone Marrow Transplant 2006; 37: 725-729.
18. Haynes A, Hunter A, McQuaker G, Anderson S, Bienz N, Russell NH. Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 1995; 16: 359-363.
19. McQuaker IG, Haynes AP, Byrne JL, Russell NH. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD341 cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Bone Marrow Transplant 1999; 24: 715-722.
20. Lerro KA, Medoff E, Wu T, Seropian SE, Snyder E, Law P et al. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplant 2003; 32: 1113-1117.
21. Bargetzi MJ, Passweg J, Baertschi E, Schoenenberger A, Gwerder C, Tichelli A et al. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transplant 2003; 31: 99-103.
22. Min YJ, Kim SW, Suh C, Huh J, Kim HS, Noh CI et al. The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF. J Korean Med Sci 2000; 15: 49-52.
23. Lefrere F, Audat F, Hermine O, Cavazzana-Calvo M, Belanger B, Arnulf B et al. The timing of granulocytecolony- stimulating factor administration after chemotherapy does not affect stem and progenitor cell apheresis yield: a retrospective study of 65 cases. Transfusion 1999; 39: 561-564.
24. Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C et al. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant 2006; 12: 316-324.
25. Milone G, Leotta S, Battiato K, Murgano P, Mercurio S, Strano A et al. Intermediate dose etoposide plus G-CSF 16 mg/ kg is more effective than cyclophosphamide 4 g/m2 plus G-CSF 10 mg/kg in PBSC mobilization of lymphoma patients. Leuk Lymphoma 2007; 48: 1950-1960.